Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

A novel tumor suppressor encoded by a 1p36.3 lncRNA functions as a phosphoinositide-binding protein repressing AKT phosphorylation/activation and promoting autophagy

Cell Death & Differentiation volume 30, pages 1166–1183 (2023)Cite this article

Subjects

Abstract

Peptides/small proteins, encoded by noncanonical open reading frames (ORF) of previously claimed non-coding RNAs, have recently been recognized possessing important biological functions, but largely uncharacterized. 1p36 is an important tumor suppressor gene (TSG) locus frequently deleted in multiple cancers, with critical TSGs like TP73, PRDM16, and CHD5 already validated. Our CpG methylome analysis identified a silenced 1p36.3 gene KIAA0495, previously thought coding long non-coding RNA. We found that the open reading frame 2 of KIAA0495 is actually protein-coding and translating, encoding a small protein SP0495. KIAA0495 transcript is broadly expressed in multiple normal tissues, but frequently silenced by promoter CpG methylation in multiple tumor cell lines and primary tumors including colorectal, esophageal and breast cancers. Its downregulation/methylation is associated with poor survival of cancer patients. SP0495 induces tumor cell apoptosis, cell cycle arrest, senescence and autophagy, and inhibits tumor cell growth in vitro and in vivo. Mechanistically, SP0495 binds to phosphoinositides (PtdIns(3)P, PtdIns(3,5)P2) as a lipid-binding protein, inhibits AKT phosphorylation and its downstream signaling, and further represses oncogenic AKT/mTOR, NF-κB, and Wnt/β-catenin signaling. SP0495 also regulates the stability of autophagy regulators BECN1 and SQSTM1/p62 through modulating phosphoinositides turnover and autophagic/proteasomal degradation. Thus, we discovered and validated a 1p36.3 small protein SP0495, functioning as a novel tumor suppressor regulating AKT signaling activation and autophagy as a phosphoinositide-binding protein, being frequently inactivated by promoter methylation in multiple tumors as a potential biomarker.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Get just this article for as long as you need it

$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Epigenomic identification of KIAA0495 as a novel 1p36.3 TSG candidate.
Fig. 2: KIAA0495 encodes a small protein SP0495.
Fig. 3: Promoter CpG methylation silences KIAA0495 in multiple tumors.
Fig. 4: SP0495 is a functional tumor suppressor in carcinoma cells.
Fig. 5: SP0495 inhibits AKT/mTOR, Wnt/β-catenin and NF-kB signaling pathways.
Fig. 6: Ectopic expression of SP0495 induces autophagy in carcinoma cells.
Fig. 7: SP0495 regulates BECN1 and p62 stability and their ubiquitination in carcinoma cells.
Fig. 8: SP0495 binds to phosphoinositides with a preference for PI3P and PI(3,5)P2.

References

  1. Henrich KO, Schwab M, Westermann F. 1p36 tumor suppression-a matter of dosage? Cancer Res. 2012;72:6079–88.

    Article  CAS  PubMed  Google Scholar 

  2. Bagchi A, Mills AA. The quest for the 1p36 tumor suppressor. Cancer Res. 2008;68:2551–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Solimini NL, Xu Q, Mermel CH, Liang AC, Schlabach MR, Luo J, et al. Recurrent hemizygous deletions in cancers may optimize proliferative potential. Science. 2012;337:104–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Kawano S, Miller CW, Gombart AF, Bartram CR, Matsuo Y, Asou H, et al. Loss of p73 gene expression in leukemias/lymphomas due to hypermethylation. Blood. 1999;94:1113–20.

    CAS  PubMed  Google Scholar 

  5. Bagchi A, Papazoglu C, Wu Y, Capurso D, Brodt M, Francis D, et al. CHD5 is a tumor suppressor at human 1p36. Cell. 2007;128:459–75.

    Article  CAS  PubMed  Google Scholar 

  6. Xinh PT, Tri NK, Nagao H, Nakazato H, Taketazu F, Fujisawa S, et al. Breakpoints at 1p36.3 in three MDS/AML(M4) patients with t(1;3)(p36;q21) occur in the first intron and in the 5’ region of MEL1. Genes Chromosomes Cancer. 2003;36:313–6.

    Article  CAS  PubMed  Google Scholar 

  7. Lin N, Di C, Bortoff K, Fu J, Truszkowski P, Killela P, et al. Deletion or epigenetic silencing of AJAP1 on 1p36 in glioblastoma. Mol Cancer Res. 2012;10:208–17.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Ingolia NT, Brar GA, Stern-Ginossar N, Harris MS, Talhouarne GJ, Jackson SE, et al. Ribosome profiling reveals pervasive translation outside of annotated protein-coding genes. Cell Rep. 2014;8:1365–79.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Fields AP, Rodriguez EH, Jovanovic M, Stern-Ginossar N, Haas BJ, Mertins P, et al. A regression-based analysis of ribosome-profiling data reveals a conserved complexity to mammalian translation. Mol Cell. 2015;60:816–27.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Calviello L, Mukherjee N, Wyler E, Zauber H, Hirsekorn A, Selbach M, et al. Detecting actively translated open reading frames in ribosome profiling data. Nat Methods. 2016;13:165–70.

    Article  CAS  PubMed  Google Scholar 

  11. Chen J, Brunner AD, Cogan JZ, Nunez JK, Fields AP, Adamson B, et al. Pervasive functional translation of noncanonical human open reading frames. Science. 2020;367:1140–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Magny EG, Pueyo JI, Pearl FM, Cespedes MA, Niven JE, Bishop SA, et al. Conserved regulation of cardiac calcium uptake by peptides encoded in small open reading frames. Science. 2013;341:1116–20.

    Article  CAS  PubMed  Google Scholar 

  13. Andrews SJ, Rothnagel JA. Emerging evidence for functional peptides encoded by short open reading frames. Nat Rev Genet. 2014;15:193–204.

    Article  CAS  PubMed  Google Scholar 

  14. Prensner JR, Enache OM, Luria V, Krug K, Clauser KR, Dempster JM, et al. Noncanonical open reading frames encode functional proteins essential for cancer cell survival. Nat Biotechnol. 2021;39:697–704.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Huang JZ, Chen M, Chen, Gao XC, Zhu S, Huang H, et al. A peptide encoded by a putative lncRNA HOXB-AS3 suppresses colon cancer growth. Mol Cell. 2017;68:171–84.e176.

    Article  CAS  PubMed  Google Scholar 

  16. Meng N, Chen M, Chen, Chen XH, Wang JZ, Zhu S, et al. Small protein hidden in lncRNA LOC90024 promotes “cancerous” RNA splicing and tumorigenesis. Adv Sci. 2020;7:1903233.

    Article  CAS  Google Scholar 

  17. Zhu S, Wang JZ, Chen D, He YT, Meng N, Chen M, et al. An oncopeptide regulates m(6)A recognition by the m(6)A reader IGF2BP1 and tumorigenesis. Nat Commun. 2020;11:1685.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Zhang M, Zhao K, Xu X, Yang Y, Yan S, Wei P, et al. A peptide encoded by circular form of LINC-PINT suppresses oncogenic transcriptional elongation in glioblastoma. Nat Commun. 2018;9:4475.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Wang Y, Wu S, Zhu X, Zhang L, Deng J, Li F, et al. LncRNA-encoded polypeptide ASRPS inhibits triple-negative breast cancer angiogenesis. J Exp Med. 2020;217:jem.20190950.

    Article  PubMed  Google Scholar 

  20. Mathew R, Karantza-Wadsworth V, White E. Role of autophagy in cancer. Nat Re Cancer. 2007;7:961–7.

    Article  CAS  Google Scholar 

  21. Santana-Codina N, Mancias JD, Kimmelman AC. The role of autophagy in cancer. Annu Rev Cancer Biol. 2017;1:19–39.

    Article  PubMed  PubMed Central  Google Scholar 

  22. Tyutyunyk-Massey L, Gewirtz DA. Roles of autophagy in breast cancer treatment: Target, bystander or benefactor. Semin Cancer Biol. 2020;66:155–62.

    Article  CAS  PubMed  Google Scholar 

  23. Tang J, Deng R, Luo RZ, Shen GP, Cai MY, Du ZM, et al. Low expression of ULK1 is associated with operable breast cancer progression and is an adverse prognostic marker of survival for patients. Breast Cancer Res Treat. 2012;134:549–60.

    Article  CAS  PubMed  Google Scholar 

  24. Li ZL, Zhang HL, Huang Y, Huang JH, Sun P, Zhou NN, et al. Autophagy deficiency promotes triple-negative breast cancer resistance to T cell-mediated cytotoxicity by blocking tenascin-C degradation. Nat Commun. 2020;11:3806.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Li Z, Chen B, Wu Y, Jin F, Xia Y, Liu X. Genetic and epigenetic silencing of the beclin 1 gene in sporadic breast tumors. BMC Cancer. 2010;10:98.

    Article  PubMed  PubMed Central  Google Scholar 

  26. Rolland P, Madjd Z, Durrant L, Ellis IO, Layfield R, Spendlove I. The ubiquitin-binding protein p62 is expressed in breast cancers showing features of aggressive disease. Endocr Relat Cancer. 2007;14:73–80.

    Article  PubMed  Google Scholar 

  27. Luo RZ, Yuan ZY, Li M, Xi SY, Fu J, He J. Accumulation of p62 is associated with poor prognosis in patients with triple-negative breast cancer. Oncol Targets Ther. 2013;6:883–8.

    Google Scholar 

  28. Lu Z, Luo RZ, Lu Y, Zhang X, Yu Q, Khare S, et al. The tumor suppressor gene ARHI regulates autophagy and tumor dormancy in human ovarian cancer cells. J Clin Invest. 2008;118:3917–29.

    CAS  PubMed  PubMed Central  Google Scholar 

  29. Ying J, Li H, Seng TJ, Langford C, Srivastava G, Tsao SW, et al. Functional epigenetics identifies a protocadherin PCDH10 as a candidate tumor suppressor for nasopharyngeal, esophageal and multiple other carcinomas with frequent methylation. Oncogene. 2006;25:1070–80.

    Article  CAS  PubMed  Google Scholar 

  30. Jin H, Wang X, Ying J, Wong AH, Cui Y, Srivastava G, et al. Epigenetic silencing of a Ca(2+)-regulated Ras GTPase-activating protein RASAL defines a new mechanism of Ras activation in human cancers. Proc Natl Acad Sci USA. 2007;104:12353–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Kim S, Heo S, Brzostowski J, Kang D. Endosomal mTORC2 is required for phosphoinositide-dependent AKT activation in platelet-derived growth factor-stimulated glioma cells. Cancers. 2021;13:2405.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Dong J, Hu Z, Wu C, Guo H, Zhou B, Lv J, et al. Association analyses identify multiple new lung cancer susceptibility loci and their interactions with smoking in the Chinese population. Nat Genet. 2012;44:895–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Zhang H, Zhai Y, Hu Z, Wu C, Qian J, Jia W, et al. Genome-wide association study identifies 1p36.22 as a new susceptibility locus for hepatocellular carcinoma in chronic hepatitis B virus carriers. Nat Genet. 2010;42:755–8.

    Article  CAS  PubMed  Google Scholar 

  34. Stacey SN, Gudbjartsson DF, Sulem P, Bergthorsson JT, Kumar R, Thorleifsson G, et al. Common variants on 1p36 and 1q42 are associated with cutaneous basal cell carcinoma but not with melanoma or pigmentation traits. Nat Genet. 2008;40:1313–8.

    Article  CAS  PubMed  Google Scholar 

  35. Hu Z, Xia Y, Guo X, Dai J, Li H, Hu H, et al. A genome-wide association study in Chinese men identifies three risk loci for non-obstructive azoospermia. Nat Genet. 2011;44:183–6.

    Article  PubMed  Google Scholar 

  36. Corn PG, Kuerbitz SJ, van Noesel MM, Esteller M, Compitello N, Baylin SB, et al. Transcriptional silencing of the p73 gene in acute lymphoblastic leukemia and Burkitt’s lymphoma is associated with 5’ CpG island methylation. Cancer Res. 1999;59:3352–6.

    CAS  PubMed  Google Scholar 

  37. Fujita T, Igarashi J, Okawa ER, Gotoh T, Manne J, Kolla V, et al. CHD5, a tumor suppressor gene deleted from 1p36.31 in neuroblastomas. J Natl Cancer Inst. 2008;100:940–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Gorringe KL, Choong DY, Williams LH, Ramakrishna M, Sridhar A, Qiu W, et al. Mutation and methylation analysis of the chromodomain-helicase-DNA binding 5 gene in ovarian cancer. Neoplasia. 2008;10:1253–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Mulero-Navarro S, Esteller M. Chromatin remodeling factor CHD5 is silenced by promoter CpG island hypermethylation in human cancer. Epigenetics. 2008;3:210–5.

    Article  PubMed  Google Scholar 

  40. Du Z, Li L, Huang X, Jin J, Huang S, Zhang Q, et al. The epigenetic modifier CHD5 functions as a novel tumor suppressor for renal cell carcinoma and is predominantly inactivated by promoter CpG methylation. Oncotarget. 2016;7:21618–30.

    Article  PubMed  PubMed Central  Google Scholar 

  41. Seki N, Ohira M, Nagase T, Ishikawa K, Miyajima N, Nakajima D, et al. Characterization of cDNA clones in size-fractionated cDNA libraries from human brain. DNA Res. 1997;4:345–9.

    Article  CAS  PubMed  Google Scholar 

  42. Pang JC, Li KK, Lau KM, Ng YL, Wong J, Chung NY, et al. KIAA0495/PDAM is frequently downregulated in oligodendroglial tumors and its knockdown by siRNA induces cisplatin resistance in glioma cells. Brain Pathol. 2010;20:1021–32.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Wu P, Mo Y, Peng M, Tang T, Zhong Y, Deng X, et al. Emerging role of tumor-related functional peptides encoded by lncRNA and circRNA. Mol Cancer. 2020;19:22.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Hartford CCR, Lal A. When long noncoding becomes protein coding. Mol Cell Biol. 2020;40:e00528–19.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Huang N, Li F, Zhang M, Zhou H, Chen Z, Ma X, et al. An upstream open reading frame in phosphatase and tensin homolog encodes a circuit breaker of lactate metabolism. Cell Metab. 2021;33:128–44.e129.

    Article  CAS  PubMed  Google Scholar 

  46. Alessi DR, James SR, Downes CP, Holmes AB, Gaffney PR, Reese CB, et al. Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Balpha. Curr Biol. 1997;7:261–9.

    Article  CAS  PubMed  Google Scholar 

  47. Li B, Cheung PY, Wang X, Tsao SW, Ling MT, Wong YC, et al. Id-1 activation of PI3K/Akt/NFkappaB signaling pathway and its significance in promoting survival of esophageal cancer cells. Carcinogenesis. 2007;28:2313–20.

    Article  CAS  PubMed  Google Scholar 

  48. Amiri A, Noei F, Jeganathan S, Kulkarni G, Pinke DE, Lee JM. eEF1A2 activates Akt and stimulates Akt-dependent actin remodeling, invasion and migration. Oncogene. 2007;26:3027–40.

    Article  CAS  PubMed  Google Scholar 

  49. Garnett MJ, Edelman EJ, Heidorn SJ, Greenman CD, Dastur A, Lau KW, et al. Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature. 2012;483:570–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Maiuri MC, Tasdemir E, Criollo A, Morselli E, Vicencio JM, Carnuccio R, et al. Control of autophagy by oncogenes and tumor suppressor genes. Cell Death Differ. 2009;16:87–93.

    Article  CAS  PubMed  Google Scholar 

  51. Vicinanza M, Korolchuk VI, Ashkenazi A, Puri C, Menzies FM, Clarke JH, et al. PI(5)P regulates autophagosome biogenesis. Mol Cell. 2015;57:219–34.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. Hasegawa J, Strunk BS, Weisman LS. PI5P and PI(3,5)P2: minor, but essential phosphoinositides. Cell Struct Funct. 2017;42:49–60.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  53. Dall’Armi C, Devereaux KA, Di, Paolo G. The role of lipids in the control of autophagy. Curr Biol. 2013;23:R33–45.

    Article  PubMed  PubMed Central  Google Scholar 

  54. Fang Y, Vilella-Bach M, Bachmann R, Flanigan A, Chen J. Phosphatidic acid-mediated mitogenic activation of mTOR signaling. Science. 2001;294:1942–5.

    Article  CAS  PubMed  Google Scholar 

  55. Li L, Zhang Y, Fan Y, Sun K, Su X, Du Z, et al. Characterization of the nasopharyngeal carcinoma methylome identifies aberrant disruption of key signaling pathways and methylated tumor suppressor genes. Epigenomics. 2015;7:155–73.

    Article  PubMed  Google Scholar 

  56. Li L, Li W, Xiao L, Xu J, Chen X, Tang M, et al. Viral oncoprotein LMP1 disrupts p53-induced cell cycle arrest and apoptosis through modulating K63-linked ubiquitination of p53. Cell Cycle. 2012;11:2327–36.

    Article  CAS  PubMed  Google Scholar 

  57. Li L, Li Z, Zhou S, Xiao L, Guo L, Tao Y, et al. Ubiquitination of MDM2 modulated by Epstein-Barr virus encoded latent membrane protein 1. Virus Res. 2007;130:275–80.

    Article  CAS  PubMed  Google Scholar 

  58. Li L, Tao Q, Jin H, van Hasselt A, Poon FF, Wang X, et al. The tumor suppressor UCHL1 forms a complex with p53/MDM2/ARF to promote p53 signaling and is frequently silenced in nasopharyngeal carcinoma. Clin Cancer Res. 2010;16:2949–58.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We thank Drs B Vogelstein, G Srivastava, GSW Tsao, Sun Young Rha, the late Dolly Huang and KT Yao for cell lines; DSMZ (Germany) for KYSE cell lines (Shimada et al., Cancer 69: 277–284 (1992); Kazusa DNA Research Institute for the full-length clone of KIAA0495; Drs Christof Niehrs and Dong-Yan Jin for TOPFlash and FOPFlash constructs; Dr. Ben CB Ko for autophagy assay, and FanFong Poon for some technical support.

Funding

This study was supported by HK-RGC (#14115019; #14115920; #14102923), NSFC (#81772869), China MOST National Key Research and Development Program (#2017YFE0191700), and Johns Hopkins Singapore/A*STAR.

Author information

Authors and Affiliations

  1. Cancer Epigenetics Laboratory, Department of Clinical Oncology, State Key Laboratory of Translational Oncology, Sir YK Pao Center for Cancer and Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, Shatin, Hong Kong

    Lili Li, Xing-sheng Shu, Hua Geng, Jianming Ying, Jie Luo, Longtao Wu, Brigette B. Y. Ma, Anthony T. C. Chan & Qian Tao

  2. School of Medicine, Shenzhen University Health Science Center, Shenzhen, China

    Xing-sheng Shu

  3. Department of Pathology, Cancer Hospital, Peking Union Medical College & Chinese Academy of Medical Sciences, Beijing, China

    Jianming Ying & Lei Guo

  4. The First Affiliated Hospital of Chongqing Medical University, Chongqing, China

    Tingxiu Xiang

  5. Chongqing University Cancer Hospital, Chongqing, China

    Tingxiu Xiang

  6. State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, China

    Xiaofeng Zhu

  7. Johns Hopkins Singapore and Sydney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Baltimore, MD, USA

    Richard F. Ambinder & Qian Tao

Authors
  1. Lili Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Xing-sheng Shu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hua Geng
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jianming Ying
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Lei Guo
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Jie Luo
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Tingxiu Xiang
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Longtao Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Brigette B. Y. Ma
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Anthony T. C. Chan
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Xiaofeng Zhu
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Richard F. Ambinder
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Qian Tao
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

QT, LL: conceptual design; LL, XS, HG, JY, LG, JL, TX, LW: performed experiments; BBM, ATC, XZ, RFA: provided materials and reviewed manuscript; LL, XS, HG, QT: drafted the manuscript; LL, QT: finalized the manuscript.

Corresponding authors

Correspondence to Lili Li or Qian Tao.

Ethics declarations

Competing interests

The authors declare no competing interests.

Ethics approval and consent to participate

The animal experiments were performed according to guidelines approved by the Institutional Ethics Committees of the First Affiliated Hospital of Chongqing Medical University and abided by the Declaration of Helsinki.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Consent for publication All authors have agreed to publish this manuscript.

Supplementary information

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and Permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Li, L., Shu, Xs., Geng, H. et al. A novel tumor suppressor encoded by a 1p36.3 lncRNA functions as a phosphoinositide-binding protein repressing AKT phosphorylation/activation and promoting autophagy. Cell Death Differ 30, 1166–1183 (2023). https://doi.org/10.1038/s41418-023-01129-w

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41418-023-01129-w

Search

Advanced search

Quick links